Skip to content
10-Q

Quarterly Report

Singular Genomics Systems, Inc.

0000950170-24-059533

← back to feed
Filed
May 14, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Apr 30, 2024 74.09M sh
Shares Diluted Q1 2024 · Mar 31, 2024 73.93M sh
Shares Diluted Q1 2024 · Mar 31, 2023 71.93M sh
Stock Repurchased Q1 2024 · Mar 31, 2024 $0
Stock Repurchased Q1 2024 · Mar 31, 2023 $7K
Capex Q1 2024 · Mar 31, 2024 $25K
Capex Q1 2024 · Mar 31, 2023 $162K
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$23.7M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$17.93M
Long Term Debt Q1 2024 · Mar 31, 2024 $7.63M
Long Term Debt Q1 2024 · Dec 31, 2023 $8.9M
Short Term Debt Q1 2024 · Mar 31, 2024 $2.63M
Short Term Debt Q1 2024 · Dec 31, 2023 $1.31M
Short Term Investments Q1 2024 · Mar 31, 2024 $126.63M
Short Term Investments Q1 2024 · Dec 31, 2023 $157.71M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $24.11M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $16.23M
Stockholders Equity Q1 2024 · Mar 31, 2024 $156.7M
Stockholders Equity Q1 2024 · Dec 31, 2023 $179.01M
Stockholders Equity Q1 2024 · Mar 31, 2023 $240.33M
Stockholders Equity Q1 2024 · Dec 31, 2022 $260.32M
Current Liabilities Q1 2024 · Mar 31, 2024 $16.08M
Current Liabilities Q1 2024 · Dec 31, 2023 $18.29M
Total Liabilities Q1 2024 · Mar 31, 2024 $82.4M
Total Liabilities Q1 2024 · Dec 31, 2023 $86.46M
Current Assets Q1 2024 · Mar 31, 2024 $166.48M
Current Assets Q1 2024 · Dec 31, 2023 $192.23M
Total Assets Q1 2024 · Mar 31, 2024 $239.1M
Total Assets Q1 2024 · Dec 31, 2023 $265.47M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.34
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.33
Eps Basic Q1 2024 · Mar 31, 2024 −$0.34
Eps Basic Q1 2024 · Mar 31, 2023 −$0.33
Sga Expense Q1 2024 · Mar 31, 2024 $14.94M
Sga Expense Q1 2024 · Mar 31, 2023 $13.2M
Rd Expense Q1 2024 · Mar 31, 2024 $11.49M
Rd Expense Q1 2024 · Mar 31, 2023 $12.23M
Net Income Q1 2024 · Mar 31, 2024 −$25.02M
Net Income Q1 2024 · Mar 31, 2023 −$23.63M
Operating Income Q1 2024 · Mar 31, 2024 −$26.85M
Operating Income Q1 2024 · Mar 31, 2023 −$25.38M
Gross Profit Q1 2024 · Mar 31, 2024 −$419K
Gross Profit Q1 2024 · Mar 31, 2023 $56K
Cost Of Revenue Q1 2024 · Mar 31, 2024 $861K
Cost Of Revenue Q1 2024 · Mar 31, 2023 $807K
Revenue Q1 2024 · Mar 31, 2024 $442K
Revenue Q1 2024 · Mar 31, 2023 $863K